Insider Selling: LENZ Therapeutics (NASDAQ:LENZ) Major Shareholder Sells $9,134,778.24 in Stock

LENZ Therapeutics, Inc. (NASDAQ:LENZ) major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of LENZ Therapeutics stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $3.36, for a total value of $9,134,778.24. Following the completion of the sale, the insider directly owned 57,559 shares in the company, valued at $193,398.24. This represents a 97.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $3.46 on Thursday. LENZ Therapeutics, Inc. has a one year low of $2.80 and a one year high of $32.13. The stock has a market capitalization of $108.71 million, a price-to-earnings ratio of -0.77 and a beta of 0.78. The stock has a 50 day moving average price of $3.99 and a 200 day moving average price of $7.89.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $4.20 million. LENZ Therapeutics had a negative net margin of 1,134.97% and a negative return on equity of 56.10%. On average, analysts predict that LENZ Therapeutics, Inc. will post -4.08 earnings per share for the current year.

More LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, including forecasting a move to profitability in 2030, and maintained a Buy rating with a $16 price target. The improved outlook may support the bullish case, though it reflects one analyst’s forecasts. Read More.
• Neutral Sentiment: Recent reporting says analysts are split on VIZZ and LENZ’s estimated fair value has moved lower, highlighting uncertainty about the product’s commercial outlook. Read More.
• Negative Sentiment: Major shareholder RA Capital Management sold 2.72 million shares for about $9.1 million, reducing its reported position by 97.93%. Such a substantial sale can weigh on sentiment. Read More.
• Negative Sentiment: The consensus price target was reportedly cut 25% to $15.30, signaling weaker analyst valuation expectations. Separately, LENZ’s latest reported quarter missed both EPS and revenue estimates, adding execution concerns. Read More. · Read More.

Hedge Funds Weigh In On LENZ Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LENZ. Pinnacle Wealth Planning Services Inc. increased its stake in shares of LENZ Therapeutics by 92.5% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 10,104 shares of the company’s stock worth $39,000 after acquiring an additional 4,854 shares during the last quarter. Inscription Capital LLC purchased a new position in shares of LENZ Therapeutics during the 3rd quarter worth $44,000. Deutsche Bank AG acquired a new position in shares of LENZ Therapeutics during the 2nd quarter valued at about $93,000. Janney Montgomery Scott LLC acquired a new position in shares of LENZ Therapeutics during the 1st quarter valued at about $99,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of LENZ Therapeutics during the 2nd quarter valued at about $102,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

Analyst Upgrades and Downgrades

LENZ has been the subject of a number of recent research reports. Weiss Ratings cut shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. Piper Sandler lowered their price target on shares of LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Monday, October 19th. HC Wainwright dropped their price objective on shares of LENZ Therapeutics to $16.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Finally, Zacks Research upgraded shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $17.50.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.